Welcome to our dedicated page for Cullinan Oncology news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a clinical-stage biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The CGEM news feed highlights the company’s ongoing clinical progress, regulatory interactions, and scientific presentations across its portfolio of T cell engagers and targeted therapies.
News updates frequently cover clinical trial data for key assets such as CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, and CLN-978, a CD19xCD3 bispecific T cell engager being studied in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. Releases detail efficacy signals, safety profiles, B cell depletion data, and outcomes in high-risk patient subsets, often presented at major medical meetings like ASH, ASCO, ESMO, ACR, and WCLC.
The CGEM news section also features updates on zipalertinib (CLN-081/TAS6417), an EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR exon 20 insertion and other uncommon mutations, developed in collaboration with Taiho Oncology and Taiho Pharmaceutical. These stories include information on Breakthrough Therapy Designation, rolling New Drug Application submissions, and data from REZILIENT trials, including cohorts with active brain metastases.
Investors and followers of Cullinan Therapeutics can use this page to review corporate updates, SEC-related announcements furnished via press release, and portfolio decisions such as program prioritizations or discontinuations. For anyone tracking CGEM, the news feed provides a consolidated view of the company’s disclosed milestones, scientific progress, and regulatory steps across its autoimmune and oncology programs.
Cullinan Oncology (NASDAQ: CGEM) announced significant leadership changes, appointing Dr. Jeffrey Jones as Chief Medical Officer and Dr. Anne-Marie Martin to its Board of Directors. Dr. Jones, previously with Bristol Myers Squibb, brings extensive oncology development experience, while Dr. Martin has over 25 years in translational medicine, most recently at GlaxoSmithKline. CEO Nadim Ahmed emphasized that their expertise will enhance Cullinan's capabilities in late-stage drug development as the company advances its pipeline of targeted cancer therapies.
Cullinan Oncology will participate in SVB Leerink’s 11th Annual Global Healthcare Conference, held virtually from February 14-18, 2022. CEO Nadim Ahmed will host a fireside chat on February 17 at 8:40 a.m. ET, available via a live webcast on the company's investor relations website. Post-event, an archive will be accessible for 30 days. The management will also engage in one-on-one meetings with investors during the conference. Cullinan focuses on developing targeted therapeutic candidates for cancer patients through innovative internal and external collaborations.
Cullinan Oncology (NASDAQ: CGEM) has entered a collaboration with the Icahn School of Medicine at Mount Sinai to develop oral protein degraders targeting HPK1, a key immune-oncology target. This multi-year agreement allows Cullinan to fund the research while holding an exclusive option to license any resulting intellectual property. The collaboration aims to enhance anti-tumor immunity through innovative therapies, co-led by experts from both institutions. The partnership reflects Cullinan's commitment to advancing cancer treatments through its diversified pipeline.
Cullinan Oncology (Nasdaq: CGEM) will present at two virtual healthcare conferences in January 2022. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 13 at 7:30 a.m. ET. A live webcast will be available on the company’s investor relations website. Additionally, the HC Wainwright BioConnect Conference will provide on-demand presentations starting January 10 at 7:00 a.m. ET. Details for registration and access can be found on their respective websites.
Cullinan Oncology announced that the FDA has granted Breakthrough Therapy Designation for CLN-081, aimed at treating patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. This designation underscores the pressing need for improved therapies in this patient demographic. Updated Phase 1/2a study results indicate a high response rate and durable outcomes in heavily pre-treated patients, along with a favorable safety profile. The company is optimistic about ongoing discussions with the FDA to advance this treatment further.
Cullinan Oncology (Nasdaq: CGEM) has reported promising interim data from its Phase 1/2a trial of CLN-081 in treating non-small cell lung cancer patients with EGFR exon 20 mutations. At the recommended Phase 2 dose of 100mg BID, the treatment demonstrated a 39% confirmed response rate and a median duration of response exceeding 15 months. Safety evaluations showed that treatment-related adverse events were predominantly mild, with no Grade 3 or greater events reported. These results support further development of CLN-081, as the company prepares for discussions with the FDA regarding late-stage trials.
Cullinan Oncology (Nasdaq: CGEM) will host a clinical update webinar on December 16, 2021, at 8:00 AM ET, focusing on its investigational drug CLN-081. This oral EGFR inhibitor targets non-small cell lung cancer patients with specific mutations. The webinar will present updated safety and efficacy data from a Phase 1/2a trial for patients whose disease has progressed after previous therapies. Interested participants can register via the company's investor website, with an archived recording available for 30 days post-webinar.
Cullinan Oncology (Nasdaq: CGEM) announced its participation in the 4th Annual Evercore ISI HealthconX Conference from November 30 to December 2, 2021. CEO Nadim Ahmed will host a virtual fireside chat on December 1 at 2:15 PM ET. The management team will also engage in one-on-one investor meetings throughout the event, with interested investors encouraged to contact their Evercore representatives. Cullinan Oncology specializes in developing targeted oncology therapies aimed at addressing critical health challenges.
Cullinan Oncology, Inc. (CGEM) reported significant updates and financial results for Q3 2021. The company’s cash and investments totaled $445.4 million, supporting its clinical pipeline. The Phase 1/2a trial for CLN-081 in advanced NSCLC is progressing, with a clinical update expected in Q4 2021. Additionally, Cullinan plans to initiate clinical trials for CLN-619 and CLN-049 by year's end. R&D expenses rose to $12.7 million, while G&A expenses increased to $5.7 million, leading to a net loss of $18.3 million.
Cullinan Oncology (Nasdaq: CGEM) has appointed Nadim Ahmed as President and CEO, effective immediately. He succeeds Owen Hughes, who transitions to Strategic Advisor after building the company’s organization and pipeline. Ahmed's extensive oncology experience includes leadership roles at Bristol Myers Squibb and Celgene, where he successfully launched key cancer therapies. The company is advancing its pipeline with plans to initiate clinical trials for its immuno-oncology programs by year-end 2021, while updating on its flagship program, Pearl, in Q4 2021.
FAQ
What is the current stock price of Cullinan Oncology (CGEM)?
What is the market cap of Cullinan Oncology (CGEM)?
